{"protocolSection":{"identificationModule":{"nctId":"NCT02767999","orgStudyIdInfo":{"id":"RC31/14/7388"},"organization":{"fullName":"University Hospital, Toulouse","class":"OTHER"},"briefTitle":"Serotonin Selective Reuptake Inhibitor (SSRI) Effects on Cerebral Connectivity in Acute Ischemic Stroke","officialTitle":"Resting State MRI Connectivity in Acute Ischemic Stroke: Serotonin Selective Reuptake Inhibitor (SSRI) in Enhancing Motor Recovery: a Placebo Controlled Study","acronym":"RECONISE"},"statusModule":{"statusVerifiedDate":"2023-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-02-27","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-01-31","type":"ACTUAL"},"completionDateStruct":{"date":"2022-01-31","type":"ACTUAL"},"studyFirstSubmitDate":"2016-05-06","studyFirstSubmitQcDate":"2016-05-06","studyFirstPostDateStruct":{"date":"2016-05-11","type":"ESTIMATED"},"lastUpdateSubmitDate":"2023-08-25","lastUpdatePostDateStruct":{"date":"2023-08-28","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"University Hospital, Toulouse","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Fluoxetine action on cerebral connectivity changes in acute ischemic stroke patients","detailedDescription":"In this placebo-controlled study, using functional resting state MRI, the investigators aim to investigate cerebral connectivity changes induced by fluoxetine given once a day for 90 days, in stroke patients with a moderate to severe motor deficit."},"conditionsModule":{"conditions":["Stroke"],"keywords":["Acute ischemic stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":25,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Fluoxetine","type":"EXPERIMENTAL","description":"One group will take a 20 mg of fluoxetine capsule per day from D0 to D90 and have fMRI","interventionNames":["Drug: Fluoxetine","Radiation: fMRI"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"The other group will take a cellulose placebo per day from D0 to D90 and have fMRI","interventionNames":["Drug: Placebo","Radiation: fMRI"]}],"interventions":[{"type":"DRUG","name":"Fluoxetine","description":"20 mg of fluoxetine capsule per day from D0 to D90","armGroupLabels":["Fluoxetine"]},{"type":"DRUG","name":"Placebo","description":"cellulose placebo per day from D0 to D90","armGroupLabels":["Placebo"]},{"type":"RADIATION","name":"fMRI","description":"functional resting state MRI","armGroupLabels":["Fluoxetine","Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Intracerebral connectivity in the motor network between fluoxetine and placebo group.","description":"Intracerebral connectivity difference in the motor network, assessed by functional resting state MRI, between fluoxetine and placebo group after the treatment.","timeFrame":"90 days"}],"secondaryOutcomes":[{"measure":"Intracerebral connectivity in the motor network between good responders patients","description":"Intracerebral connectivity difference in the motor network, assessed by functional resting state MRI, in fluoxetine and placebo good responders patients, defined by :\n\n* 8 points gain on the National Institute of Health Stroke Scale (NIHSS), assessed between D0 and D30 and between D0 and D90\n* or 2 points gain on the modified Rankin score (mRS) assessed between D0 and D30 and between D0 and D90.","timeFrame":"90 days"},{"measure":"Intracerebral connectivity in the motor network between non-responders patients","description":"Intracerebral connectivity difference in the motor network, assessed by functional resting state MRI, in non-responders patients of fluoxetine and placebo group.","timeFrame":"90 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* First-ever ischemic stroke\n* Cortical or subcortical stroke\n* National Institute of Health Stroke Scale NIHSS\\>12 or motor NIHSS\\>6 at inclusion\n* MRI-proved ischemic stroke\n\nExclusion Criteria:\n\n* pregnant or breast-feeding women\n* alcoholism\n* ongoing Selective Serotonin Reuptake Inhibitor treatment or interruption \\< 1 month\n* allergic reaction after SSRI administration\n* MRI contraindication\n* NIHSS\\>22\n* Severe aphasia\n* Coma","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"François CHOLLET, MD PhD","affiliation":"University Hospital, Toulouse","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Hôpital Pellegrin","city":"Bordeaux","country":"France","geoPoint":{"lat":44.84044,"lon":-0.5805}},{"facility":"CHU Toulouse","city":"Toulouse","zip":"31059","country":"France","geoPoint":{"lat":43.60426,"lon":1.44367}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000005473","term":"Fluoxetine"}],"ancestors":[{"id":"D000017367","term":"Selective Serotonin Reuptake Inhibitors"},{"id":"D000014179","term":"Neurotransmitter Uptake Inhibitors"},{"id":"D000049990","term":"Membrane Transport Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000018490","term":"Serotonin Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000018687","term":"Antidepressive Agents, Second-Generation"},{"id":"D000000928","term":"Antidepressive Agents"},{"id":"D000011619","term":"Psychotropic Drugs"},{"id":"D000065690","term":"Cytochrome P-450 CYP2D6 Inhibitors"},{"id":"D000065607","term":"Cytochrome P-450 Enzyme Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"}],"browseLeaves":[{"id":"M8291","name":"Fluoxetine","asFound":"Prevalence","relevance":"HIGH"},{"id":"M15202","name":"Serotonin","relevance":"LOW"},{"id":"M19339","name":"Selective Serotonin Reuptake Inhibitors","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"},{"id":"M3937","name":"Antidepressive Agents","relevance":"LOW"},{"id":"M14164","name":"Psychotropic Drugs","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M30227","name":"Cytochrome P-450 Enzyme Inhibitors","relevance":"LOW"}],"browseBranches":[{"abbrev":"PsychDr","name":"Psychotropic Drugs"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}